Nitrous Oxide
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Nitrous Oxide
- Pharmacist Assessment Report
- Nitrous Oxide: From Analgesic/Anxiolytic Gas to Benign Prostatic Hyperplasia
- One-Sentence Summary
- Quick Overview
- Why is This Prediction Reasonable?
- Clinical Trial Evidence
- Literature Evidence
- Canada Market Information
- Safety Considerations
- Conclusion and Next Steps
- Disclaimer
Nitrous Oxide: From Analgesic/Anxiolytic Gas to Benign Prostatic Hyperplasia
One-Sentence Summary
Nitrous oxide is an inhaled gas used for analgesia and anxiety relief, marketed in Canada under 6 licences. The TxGNN model predicts it may be effective for benign prostatic hyperplasia (BPH), but the support is weak: 1 clinical trial (indirect, procedural) and 1 publication (a case report) are available, and neither tests BPH treatment.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not specified in the licence data (product names such as “Analgesic Gas” suggest analgesic use) |
| Predicted New Indication | Benign prostatic hyperplasia (disease) |
| TxGNN Prediction Score | 0.9952 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 6 of 6) |
| Number of DINs | 6 (marketed: 6) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on general pharmacology, nitrous oxide is an NMDA-receptor antagonist and an inhaled anxiolytic and analgesic.
A credible mechanistic link to BPH is lacking. Nitrous oxide has no known effect on prostate growth, androgen signalling, or the smooth muscle tone of the lower urinary tract. The high TxGNN score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, not biological evidence, and is not backed by pharmacological rationale.
The only real connection is procedural. Nitrous oxide is used to control anxiety and pain during prostate procedures such as transrectal biopsy. That is symptom or procedural support, not treatment of the underlying disease.
Clinical Trial Evidence
| Trial Number | Phase | Status | Enrollment | Key Findings |
|---|---|---|---|---|
| NCT05803096 | Phase 4 | Completed | 143 | Self-administered nitrous oxide during transrectal prostate biopsy to reduce anxiety and pain. It addresses procedural comfort, not BPH outcomes (e.g. symptom score, prostate volume, urinary flow). Relevance: indirect only. |
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 9223887 | 1997 | Case report | Masui (Japanese Journal of Anesthesiology) | Anaesthetic management of a patient with pure autonomic failure undergoing suprapubic prostatectomy. It describes anaesthesia care, not a therapeutic effect on BPH. |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02014467 | NITROUS OXIDE USP | Not specified | Not specified |
| 02154811 | NITROUS OXIDE U.S.P. | Not specified | Not specified |
| 00572845 | NITROUS OXIDE 100% | Not specified | Not specified |
| 00693596 | LIQUI-MED ANALGESIC GAS | Not specified | Not specified |
| 02154757 | MEOPA | Not specified | Not specified |
A sixth licence, ALNOX GAS (DIN 02071010), is also valid.
Safety Considerations
- Drug Interactions (5 recorded; one Major, four Moderate):
- Methotrexate: Major
- Morphine: Moderate
- Opium: Moderate
- Codeine: Moderate
- Hydrocodone: Moderate
Package insert warnings and contraindications were not available in the compiled data. Please refer to the package insert for further safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The high TxGNN score is not supported by pharmacological rationale or direct clinical evidence. The single trial concerns anxiety and pain during prostate biopsy, and the single publication is an anaesthesia case report. Neither tests nitrous oxide as a treatment for BPH.
To proceed, the following is needed:
- A plausible mechanistic hypothesis linking nitrous oxide to BPH pathophysiology
- Preclinical or clinical studies with BPH-specific endpoints (e.g. IPSS, prostate volume, urinary flow)
- Health Canada package insert warnings and contraindications for safety screening
- Detailed mechanism of action data
- Clarification of the approved indications and dosage forms for the Canadian licences
- A decision on whether the procedural-support use (anxiety and pain control during prostate procedures) is the real opportunity, since it is a different question from treating BPH
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.